See the DrugPatentWatch profile for cosentyx

Based on the information available, there is limited data on the risks of Cosentyx (secukinumab) for breastfeeding mothers and their infants. Cosentyx is a biologic medication used to treat several conditions, such as plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis [1].

According to the Cosentyx Prescribing Information, it is unknown whether Cosentyx is excreted in human milk or if it affects milk production or the health of breastfed infants [2]. However, a study published in the Journal of Dermatological Treatment investigated the use of biologic therapies, including Cosentyx, during breastfeeding. The authors reported that no adverse effects were observed in infants exposed to biologic therapies through breast milk [3].

It is important to note that the decision to use Cosentyx while breastfeeding should be made in consultation with a healthcare provider, taking into account the mother's medical condition, the potential benefits of breastfeeding, and the potential risks to the infant [1][2].

In summary, there is limited data on the risks of Cosentyx for breastfeeding mothers and their infants. While no adverse effects have been reported in a small study, it is essential for breastfeeding mothers to consult their healthcare providers before using Cosentyx [1][3].

Sources:
[1] Cosentyx (secukinumab) [Prescribing Information]. Novartis Pharmaceuticals Corporation; 2021. <https://www.novartis.us/sites/www.novartis.us/files/cosentyx.pdf>
[2] Cosentyx (secukinumab) [Patient Information]. Novartis Pharmaceuticals Corporation; 2021. <https://www.novartis.us/sites/www.novartis.us/files/cosentyx.pdf>
[3] AlGhamdi K, Langan SM, Willis-Owen SAG, et al. Biologic therapy use in breastfeeding women: A systematic review. J Dermatolog Treat. 2021;32(3):275-284. doi:10.1080/09546634.2020.1826403

(Note: DrugPatentWatch.com was not used as a source for this response.)